Craft

Coya Therapeutics

Stock Price

$7.4

2024-10-29

Market Capitalization

$170.5 M

2024-10-29

Revenue

$7.9 M

FY, 2025

Coya Therapeutics Summary

Company Summary

Overview
Coya Therapeutics is a company that provides cell therapy platform developing treatments focused on the biology and potential therapeutic advantages of regulatory T cells (Tregs) to target systemic inflammation and neuroinflammation. Its product candidate pipeline leverages multiple therapeutic modalities aimed at restoring the anti-inflammatory and immunomodulatory functions of Tregs. The company is focused on the advancement of therapeutic approaches to address the medical needs of patients with neurodegenerative, autoimmune, and metabolic diseases.
Type
Public
Status
Active
Founded
2020
HQ
Houston, TX, US | view all locations
Website
https://coyatherapeutics.com/
Cybersecurity rating
Sectors

Key People

  • Howard Berman

    Howard Berman, Chief Executive Officer and Chairman of the Board

  • Adrian Hepner

    Adrian Hepner, President and Chief Medical Officer

  • David S. Snyder

    David S. Snyder, Chief Financial Officer and Chief Operating Officer

  • Aaron Thome

    Aaron Thome, Head of Neuroinflammation Platform

LocationsView all

1 location detected

  • Houston, TX HQ

    United States

    5850 San Felipe St Suite 500

Coya Therapeutics Financials

Summary Financials

Revenue (Q1, 2026)
$251.1K
Net income (Q1, 2026)
($7.2M)
Cash (Q1, 2026)
$50.7M
EBIT (Q1, 2026)
($7.6M)

Footer menu